FDA Accepts Tyvaso Filing for Idiopathic Pulmonary Fibrosis

Company: United Therapeutics · Drug: Tyvaso (Treprostinil) · Indication: Idiopathic Pulmonary Fibrosis · Regulatory Action: sNDA Accepted for Review · Date: September 2, 2026 Summary The U.S. Food and Drug Administration accepted United Therapeutics’ supplemental New Drug Application for nebulized Tyvaso (treprostinil) in idiopathic pulmonary…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

BMS – Anthropic AI Partnership
J&J Secures Option on Sail’s In Vivo CAR-T Platform
Gossamer Bio Ties $250 Million Financing to FDA Milestones After Mixed PROSERA Result
Ipsen to Acquire Memo Therapeutics for Up to EUR700M